A Randomized, Double-Blind, 2-Period Crossover Trial to Determine the Relative Bioavailability of CE-Iohexol (Iohexol/Sulfobutylether-β-Cyclodextrin (Captisol) Injection and Omnipaque (Iohexol) Injection in Healthy Adult Volunteers
Latest Information Update: 17 Nov 2019
At a glance
- Drugs Iohexol (Primary)
- Indications Cardiovascular disorders
- Focus Pharmacokinetics; Registrational
- Sponsors CyDex Pharmaceuticals
Most Recent Events
- 08 Nov 2019 According to a Ligand Pharmaceuticals media release, data from this trial was presented at the ASN Kidney Week 2019.
- 08 Nov 2019 Results published in the Ligand Pharmaceuticals media release
- 05 Nov 2019 According to a Ligand Pharmaceuticals media release, data from this trial will be presented at ASN Kidney Week 2019 in Washington, DC on November 8th, 2019 and the 2019 Contrast Media Research Symposium in Erice, Italy on November 11th, 2019.